UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals [MarketWatch]
Minerva Neurosciences, Inc (NERV)
Last minerva neurosciences, inc earnings: 3/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.minervaneurosciences.com/investor-relations
Company Research
Source: MarketWatch
UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals Minerva Neurosciences Inc. shares NERV, +64.54% soared 34% in premarket trade Monday, after the company said its trial of Seltorexant as a treatment for insomnia met its primary and key secondary goals. The company said the Phase 2b trial of the drug met its primary endpoint of latency to persistent sleep, or LPS, at Night 1 in 10 mg and 20 mg doses of Seltorexant. It also met its key secondary endpoint, defined as wake after sleep onset over first 6 hours at Night 1. The beneficial effects were maintained over time and were consistent in adults and elderly patients. "The findings from this study demonstrate that seltorexant significantly improves sleep induction and prolongs sleep duration," said Professor Thomas Roth, Director of the Sleep Disorders and Research Center at Henry Ford Hospital. "The results also demonstrate that seltorexant showed a significantly greater improvement in the
Show less
Read more
Impact Snapshot
Event Time:
NERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NERV alerts
High impacting Minerva Neurosciences, Inc news events
Weekly update
A roundup of the hottest topics
NERV
News
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
NERV
Earnings
- 11/5/24 - Beat
NERV
Analyst Actions
- 11/6/24 - HC Wainwright
NERV
Sec Filings
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- NERV's page on the SEC website